Abstract:Background: ATP-binding cassette subfamily G member 2 (ABCG2), a member of the ABC transporter superfamily proteins, mediates multidrug resistance (MDR) by transporting substrate anticancer drugs out of cancer cells and decreasing their intracellular accumulation. MDR is a major hurdle to successful chemotherapy. A logical approach to overcome MDR is to inhibit the transporter. However, no safe and effective MDR inhibitor has been approved in the clinic. Methods: The MTT assay was used to evaluate cell cytotoxicity and MDR reversal effect. Drug efflux and intracellular drug accumulation were measured by flow cytometry. The H460/MX20 cell xenograft model was established to evaluate the enhancement of anticancer efficacy of topotecan by dacomitinib in vivo. To ascertain the interaction of dacomitinib with the substrate binding sites of ABCG2, the competition of dacomitinib for photolabeling of ABCG2 with [125I]- iodoarylazidoprazosin (IAAP) was performed. Vanadate-sensitive ATPase activity of ABCG2 was measured in the presence of a range of different concentrations of dacomitinib to evaluate the effect of dacomitinib on ATP hydrolysis as the energy source of the transporter. A flow cytometry-based assay and western blotting were employed to study whether dacomitininb could inhibit the expression level of ABCG2. The mRNA expression levels of ABCG2 were analyzed by real-time quantitative RT-PCR. The protein expression level of AKT, ERK and their phosphorylations were detected by Western blotting. Results: Here, we found that dacomitinib, an irreversible pan-ErbB tyrosine kinase inhibitor (TKI) in phase III clinical trial, could enhance the efficacy of conventional chemotherapeutic agents specifically in ABCG2-overexpressing MDR cancer cells but not in the parental sensitive cells. Dacomitinib was found to significantly increase the accumulation of ABCG2 probe substrates [doxorubicin (DOX),Rhodamine 123 (Rho 123) and Hoechst 33342] by inhibiting the transporter efflux function. Moreover, dacomitinib stimulated ABCG2 ATPase activity and competed with [125I]-IAAP photolabeling of ABCG2 in a concentration-dependent manner. However, dacomitinib did not alter ABCG2 expression at protein and mRNA levels or inhibit ErbB downstream signaling of AKT and ERK. Importantly, dacomitinib significantly enhanced the efficacy of topotecan in ABCG2-overexpressing H460/MX20 cell xenografts in nude mice without incurring additional toxicity. Conclusions: These results suggest that dacomitinib reverses ABCG2-mediated MDR by inhibiting ABCG2 efflux function and increasing intracellular accumulation of anticancer agents. Our findings advocate further clinical investigation of combinations of dacomitinib and conventional chemotherapy in cancer patients with ABCG2-overexpressing MDR tumors.

Axitinib Targeted Cancer Stem Like Cells to Enhance Efficacy of Chemotherapeutic Drugs Via Inhibiting the Drug Transport Function of Abcg2

Apatinib (YN968D1) Enhances the Efficacy of Conventional Chemotherapeutical Drugs in Side Population Cells and ABCB1-overexpressing Leukemia Cells

Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by an Aurora Kinase Inhibitor CCT129202

Tandutinib (mln518/ct53518) Targeted to Stem-Like Cells by Inhibiting the Function of Atp-Binding Cassette Subfamily G Member 2

Data from Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.

Cancer esearch apeutics , Targets , and Chemical Biology tinib ( YN 968 D 1 ) Reverses Multidrug Resistance by biting the Efflux Function of Multiple ATP-Binding R sette Transporters

Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter

Analysis of ABCG2 Expression and Side Population Identifies Intrinsic Drug Efflux in the HCC Cell Line MHCC-97L and Its Modulation by Akt Signaling.

The Epidermal Growth Factor Tyrosine Kinase Inhibitor Ag1478 and Erlotinib Reverse Abcg2-Mediated Drug Resistance

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2

The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug efflux

Alectinib (CH5424802) Antagonizes ABCB1- and ABCG2-mediated Multidrug Resistance in Vitro, in Vivo and Ex Vivo.

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells

Combined Treatment of Apatinib with Docetaxel in Non-Small-Cell Lung Cancer Mice and Its Material Basis of Pharmacokinetics.

Suppression of ABCG2 Mediated MDR in Vitro and in Vivo by a Novel Inhibitor of ABCG2 Drug Transport

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

Synergistic Anti-Tumor Effects of Axitinib and Doxorubicin

Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells

Nilotinib Potentiates Anticancer Drug Sensitivity in Murine ABCB1-, ABCG2-, and ABCC10-multidrug Resistance Xenograft Models.

Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo